Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 96

Sort by

Sort Order Select

Journal Articles

Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing

Tomas Radivoyevitch, Brian J. Druker, Jerry Radich, Hagop Kantarjian, Wenlong Tang, Michael J. Hanley, Mingxi M. Song, Timothy Smith, Dean Bottino

Blood (2022) 140 (Supplement 1): 6793–6795.

https://doi.org/10.1182/blood-2022-159194

Published: 2022

Journal Articles

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Blood (2021) 138 (19): 1885–1895.

https://doi.org/10.1182/blood.2020010603

Published: 2021

Includes: Supplemental data

Journal Articles

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes

Yasunobu Nagata, Ran Zhao, Hassan Awada, Cassandra M. Kerr, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, Hideki Makishima, Tomas Radivoyevitch, Jacob G. Scott, Mikkael A. Sekeres, Brian P. Hobbs, Jaroslaw P. Maciejewski

Blood (2020) 136 (20): 2249–2262.

https://doi.org/10.1182/blood.2020005488

Published: 2020

Includes: Supplemental data

Journal Articles

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139013

Published: 2020

Journal Articles

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

Ashwin Kishtagari, MBBS, Hassan Awada, Reda Z. Mahfouz, MD PhD, Teodora Kuzmanovic, Jibran Durrani, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Alan Lichtin, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 1279.

https://doi.org/10.1182/blood-2019-130579

Published: 2019

Journal Articles

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

Yihong Guan, PhD, Anand D. Tiwari, PhD, James G Phillips, PhD, Metis Hasipek, PhD, Dale Grabowski, BS, Cassandra M Kerr, MS, Vera Adema, PhD, Yasunobu Nagata, MD PhD, Valeria Visconte, PhD, Tomas Radivoyevitch, PhD, Daniel Lindner, MD PhD, Manja Meggendorfer, PhD, Mohamed Abazeed, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD, Babal K. Jha, PhD

Blood (2019) 134 (Supplement_1): 880.

https://doi.org/10.1182/blood-2019-131920

Published: 2019

Journal Articles

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

Yasunobu Nagata, MD PhD, Ran Zhao, Hassan Awada, Cassandra M Kerr, MS, Abhinav Goyal, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Jacob Scott, MD, Mikkael A. Sekeres, MD MS, Brian P. Hobbs, PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1716.

https://doi.org/10.1182/blood-2019-127285

Published: 2019

Journal Articles

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 16.

https://doi.org/10.1182/blood-2019-130319

Published: 2019

Journal Articles

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

Yasunobu Nagata, MD PhD, Hideki Makishima, MD PhD, Cassandra M Kerr, MS, Bhumika J. Patel, MD, Hassan Awada, Vera Adema, PhD, Valeria Visconte, PhD, Sudipto Mukherjee, MD PhD MPH, Thomas Laframboise, PhD, Aziz Nazha, MD, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Seishi Ogawa, MD PhD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 2992.

https://doi.org/10.1182/blood-2019-128893

Published: 2019

Journal Articles

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Christina A. Snider, BA, Kevin Fung, Francesca Gould, Vera Adema, PhD, Cassandra M Kerr, MS, Sunisa Kongkiatkamon, Hassan Awada, MD, Milo Co, Teodora Kuzmanovic, BA, Bhumika J. Patel, MD, Aaron T. Gerds, MD MS, Sudipto Mukherjee, MD PhD MPH, Aziz Nazha, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Jaroslaw P. Maciejewski, MD PhD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Anjali S. Advani, MD

Blood (2019) 134 (Supplement_1): 2696.

https://doi.org/10.1182/blood-2019-126311

Published: 2019

Journal Articles

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Xiaorong Gu, PhD, Rita Tohme, PhD, Benjamin K. Tomlinson, MD, Lisa Durkin, Caroline Schuerger, Asmaa M Zidan, MB, BCh, Tomas Radivoyevitch, PhD, Hetty E. Carraway, MD MBA, Ronald Sobecks, MD, Betty K. Hamilton, MD, Alan Lichtin, MD, Jaroslaw P. Maciejewski, MD PhD, Yogenthiran Saunthararajah, MD

Blood (2019) 134 (Supplement_1): 537.

https://doi.org/10.1182/blood-2019-125823

Published: 2019

Journal Articles

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Abby Statler, PhD MPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Sudipto Mukherjee, MD PhD MPH, Kimberly Bell, MBA, RN, BSN, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 381.

https://doi.org/10.1182/blood-2019-129096

Published: 2019

Journal Articles

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Blood (2019) 134 (Supplement_1): 3836.

https://doi.org/10.1182/blood-2019-128853

Published: 2019

Journal Articles

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

Hassan Awada, Arda Durmaz, Yasunobu Nagata, MD PhD, Teodora Kuzmanovic, Ashwin Kishtagari, MBBS, Jibran Durrani, Cassandra M Kerr, MS, Anjali S. Advani, MD, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Manja Meggendorfer, PhD, Aziz Nazha, MD, Valeria Visconte, PhD, Mikkael A. Sekeres, MD MS, Torsten Haferlach, MD, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1406.

https://doi.org/10.1182/blood-2019-132031

Published: 2019

Journal Articles

LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Courtney Hershberger, BS, James Hiznay, Rosemary Dietrich, Xiaorong Gu, PhD, Cassandra M. Hirsch, Amy Graham, BS, MS, Bartlomiej P. Przychodzen, Valeria Visconte, PhD, Vera Adema, PhD, Yvonne Parker, Hetty E. Carraway, MD MBA, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Yogenthiran Saunthararajah, MD, Jaroslaw P. Maciejewski, Richard A Padgett

Blood (2018) 132 (Supplement 1): 3073.

https://doi.org/10.1182/blood-2018-99-112838

Published: 2018

Journal Articles

Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA

Sudipto Mukherjee, MD PhD MPH, Tomas Radivoyevitch, PhD, Brian P. Hobbs, PhD, Xuefei Jia, MS, Rami S. Komrokji, MD, David P. Steensma, MD, Amy E. DeZern, MD, Gail J. Roboz, MD, Guillermo Garcia-Manero, MD, Jaroslaw P. Maciejewski, Aziz Nazha, Mikkael A. Sekeres, MD MS

Blood (2018) 132 (Supplement 1): 3095.

https://doi.org/10.1182/blood-2018-99-119146

Published: 2018

Journal Articles

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Teodora Kuzmanovic, Bhumika J. Patel, MD, Srinivasa Reddy Sanikommu, MD, Yasunobu Nagata, Hassan Awada, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Remco J Molenaar, MD PhD, Babal K. Jha, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, Tomas Radivoyevitch, PhD

Blood (2018) 132 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2018-99-119950

Published: 2018

Journal Articles

Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Blood (2018) 132 (Supplement 1): 1805.

https://doi.org/10.1182/blood-2018-99-115154

Published: 2018

Journal Articles

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Raffi Tchekmedyian, BS, Tomas Radivoyevitch, PhD, Aaron T. Gerds, MDMS, Aziz Nazha, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Jaroslaw P. Maciejewski, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MDPhDMPH

Blood (2018) 132 (Supplement 1): 371.

https://doi.org/10.1182/blood-2018-99-119661

Published: 2018

Journal Articles

Distinct Features of Chip-Derived and De Novo MDS

Blood (2018) 132 (Supplement 1): 2572.

https://doi.org/10.1182/blood-2018-99-117763

Published: 2018

NARROW

Chronic-Phase Chronic Myeloid Leukemia Times to Death By Disease Support Tyrosine Kinase Inhibitor Dose Reductions When BCR::ABL1 Level Is <1% and Decreasing

Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia

Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes

The Application of Machine Learning to Improve the Subclassification and Prognostication of Acute Myeloid Leukemia

Extended Experience with a Very Low Dose, Metronomic, Subcutaneous Decitabine Regimen Intended to Deplete DNMT1 without Cytotoxicity

TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia

How Morphologic Features Are Shaped By Underlying Somatic Genotype in MDS

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Mutational Type and Configuration of an Individual Gene May Differentially Impact the Clinical and Phenotypic Features

RORA Is a Potential Prognostic Biomarker and Therapeutic Target for Patients with Acute Myeloid Leukemia

Feedback Responses of the Pyrimidine Metabolism Network Mediate Resistance to Decitabine and 5-Azacytidine

Are Racial Disparities in Acute Myeloid Leukemia (AML) Clinical Trial Enrollment Associated with Comorbidities and/or Organ Dysfunction?

Determinants of "Fitness" for Intensive Therapy Among Acute Myeloid Leukemia (AML) Patients

Towards Molecularly Informed Acute Myeloid Leukemia Subtyping Reflective of Pathogenesis

LUC7L2 Is a Novel RNA-Splicing Regulatory Factor Mutated in Myelodysplastic Syndromes

Evaluating the Evidence for Long-Term Benefit from Specialty Centers Versus Real World for MDS Patients Treated with HMA

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Biallelic TET2 Inactivation in Myeloid Neoplasia: From Clonal Hierarchy to Clinical Phenotypes

Survival Outcomes of Patients with Therapy-Related Myelodysplastic Syndromes in the United States

Distinct Features of Chip-Derived and De Novo MDS

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only